• New data shows the Accelerate Arc System enables automated and rapid sample preparation that yields robust reportability and accurate microbial identification for positive blood cultures using MALDI when compared to conventional MALDI methods

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, today announced the release of new data on the Accelerate Arc Module and BC kit at the 32nd European Congress for Clinical Microbiology and Infectious Diseases (ECCMID) located in Lisbon, Portugal 23-26 April 2022.  “The internal study data demonstrated 94% or greater accuracy on positive blood cultures processed using the Arc Module and BC kit, on the Bruker Biotyper and bioMérieux Vitek MS Systems when compared to conventional MALDI,” said Shelley Campeau, PhD, D(ABMM), co-author of the studies and Director of Scientific and Clinical Affairs, Accelerate Diagnostics. “In addition, a study conducted at the Medical College of Wisconsin showed that Arc-processed samples* yielded 100% agreement, a majority of which had high confidence scores, when compared to conventional MALDI. This data represents an important step in providing a workflow solution to help automate sample preparation for rapid and accurate microbial identification, saving hours of wait time and numerous manual steps to deliver results.”  The first study seeded samples for 20 of the most prevalent organism species (a total of 100 isolates) incubated on the BD Bactec FX blood culture system. After flagging positive, the samples were processed on the Arc BC kit and module, and subsequently tested in triplicate on both the Bruker Biotyper and bioMérieux Vitek MS MALDI systems, and results from Arc-processed samples were compared to conventional colony MALDI. The study found the Arc-processed samples had an overall agreement of 100% on the Bruker Biotyper, and 94% on the Vitek MS.  The second study conducted with the Medical College of Wisconsin processed 50 fresh positive blood cultures from the VersaTrek blood culture system on the Arc Module and were subsequently tested in triplicate on the Bruker MALDI system, with results from the Arc compared to conventional colony MALDI. The study found the Arc enabled direct identification of microorganisms in 90% of blood cultures, and there was 100% agreement between the Arc and colony identification. In addition, Arc enabled the identification in less than 90 minutes, with less than five minutes of hands-on time.    *Both studies were conducted using the Research Use Only Accelerate Arc BC Kit. Two poster presentations featuring performance of the Accelerate Arc System will be presented on Monday April 25th, 12:00- 13:00 hr, Pavilion 3 of the Feira Internacional de Lisboa (FIL).  Poster Presentations P1219 Analytical Performance of the Automated Accelerate Arc BC kit and Module for Direct Identification from Positive Blood Cultures using MALDI Authored by: B. Mesich, D. Gerstbrein, A. Cruz, M. Faron, S. Campeau, and B. Buchan P1039 Evaluation of the Accelerate Arc module and BC kit for isolation of microorganisms from positive blood culture broths and suitability for MALDI-ToF analysis Authored by: A. Campos-Alvarez, S. Bolanos, K. Lank, R. Nyberg, S. Campeau, and C. Michel For further information on the Accelerate Arc System at ECCMID, please visit Booth 1-31 at the Altice Arena exhibit space.  For more information on ECCMID, please visit their website at www.eccmid.org.